-
公开(公告)号：US20220211762A1
公开(公告)日：2022-07-07
申请号：US17607389
申请日：2020-04-27
发明人： Kyuboem HAN , Chun-Hyung KIM , Shin-Hye YU , Seo-Eun LEE , Sang-Min LIM , Hahnsun JUNG , Kwangmin NA , Yoon Mi HAN , Jun Young SON , Jong-Cheon HA , Kyunghee JUNG , Young-Cheol KANG , Eun-Seo LEE , Mi Jin KIM , Yong-Soo CHOI , Jung Uk HWANG , Min Ji LEE , Kyuseok KIM , Tae Nyoung CHUNG
摘要： The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1β, TNF-α and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.
-
公开(公告)号：US20220211754A1
公开(公告)日：2022-07-07
申请号：US17607850
申请日：2020-04-29
发明人： Kyuboem HAN , Chun-Hyung KIM , Shin-Hye YU , Seo-Eun LEE , Sang-Min LIM , Hahnsun JUNG , Kwangmin NA , Yoon Mi HAN , Jun Young SON , Eun Young LEE , Jeong Yeon KIM , Yeong Wook SONG , Jin Chul PAENG , Yun Sang LEE , Do Won HWANG
IPC分类号： A61K35/12 , A61K35/30 , A61K35/17 , A61K35/33 , A61K35/19 , A61K35/35 , A61K35/28 , A61K35/34 , A61K35/50 , A61K35/52 , A61K35/54 , A61K35/545
摘要： The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1β, TNF-α, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.
-
搜索结果
2 条记录 (耗时 0.011 秒)
